This study, conducted at a needle exchange program, found that 23 of 24 participants could use Previct Drugs independently after brief training, even while under the influence of multiple substances. The study situates the findings in a broader market context: substance use is a global and costly challenge, and digital solutions are needed to expand access to treatment.
“Previct Drugs is useful even among the most challenging client populations—and could become a key component of future addiction care.”